Gemcitabine plus S-1 versus gemcitabine alone in the treatment of advanced pancreatic cancer: a Meta-analysis
10.3760/cma.j.issn.1673-422X.2014.03.023
- VernacularTitle:吉西他滨联合替吉奥与吉西他滨单药化疗治疗晚期胰腺癌比较的Meta分析
- Author:
Yifan JIANG
;
Jiangping GONG
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Drug therapy;
Meta-analysis;
Gemcitabine
- From:
Journal of International Oncology
2014;41(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the gemcitabine (GEM) plus S-1 and gemcitabine alone in the treatment of advanced pancreatic cancer (PC) by meta-analysis.Methods Articles were searched in PubMed,Cochrane library,Embase,CNKI,and CBM up to August 1st,2013.Only randomized controlled trails (RCTs) for GEM + S-1 and GEM alone in advanced PC were included.Two reviewers retrieved and collected data respectively.Data were selected basing on inclusion and exclusion criteria.The meta-analysis was base on survival advantage (include overall survival and progress free survival),object response rate,disease control rate and adverse reaction.Results A total of 3 trials with 772 cases were included.Meta-analysis demonstrated that GEM plus S-1 significantly improved the progress free survival (HR:0.64,95％CI:0.54-0.75,P ＜ 0.000 01) and overall survival (HR:0.81,95％CI:0.68-0.96,P =0.01),improved object response rate (RD:0.16,95％ CI:0.10-0.21,P ＜ 0.000 01) and disease control rate (RD:0.10,95％ CI:0.03-0.17,P =0.009) also.However,the incidence of WHO 3/4 grade adverse reaction was increased significantly in the GEM + S-1 group.Neutropenia,thrombocytopenia,and gastrointestinal reaction were increased by 18％ (P =0.02),18％ (P =0.008) and 8％ (P ＜ 0.000 01)respectively.Conclusion GEM combined with S-1 can improve the chemotherapy effect compared with GEM alone.The adverse reactions also increase significantly,but the overall survival is benefit.
